MET-HM401B-100μg / 询价
MET-HM401B-500μg / 询价
MET-HM401B-500μgx2 / 询价
Biotinylated Human HGF R/c-MET Protein
Recombinant Biotinylated Human HGF R/c-MET Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Glu25-Thr932 [Accession | P08581-1].
The mature form of HGF R is a heterodimer which can be cleaved into α and β chain. The protein has a predicted MW of 32.5 kDa (α chain) and 72.1 kDa (β chain). Due to glycosylation, the protein migrates to 45-50 kDa and 80-90 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human HGF R on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HGF R is greater than 95% as determined by SEC-HPLC.
Immobilized Anti-HGF R Antibody, hFc Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Human HGF R, His Tag with the EC50 of 25.7ng/ml determined by ELISA.
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGF R), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1.
MET; oncogene MET; HGF R; HGF/SF receptor; AUTS9; cMET; Met (c-Met); RCCP2; SF receptor
(1)Sierra J. c-MET as a potential therapeutic target and biomarker in cancer[J]. Therapeutic Advances in Medical Oncology, 2011, 3(1 Suppl):21-35.
